Last $0.13 USD
Change Today 0.00 / 0.00%
Volume 1.0K
BZYR On Other Exchanges
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

burzynski research institute (BZYR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/30/14 - $0.50
52 Week Low
06/19/14 - $0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

burzynski research institute (BZYR) Related Businessweek News

No Related Businessweek News Found

burzynski research institute (BZYR) Details

Burzynski Research Institute, Inc. operates a research and development facility of Antineoplaston drugs being tested for use in the treatment of cancer. The company focuses on the research, development, production, marketing, promotion, and sale of medical chemical compounds, such as growth-inhibiting peptides, amino acid derivatives, and organic acids. It is conducting Phase II clinical trial of Antineoplaston drugs. The company also provides consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.

2 Employees
Last Reported Date: 05/30/14
Founded in 1977

burzynski research institute (BZYR) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: --
Secretary and Treasurer
Total Annual Compensation: --
Vice President of Clinical Trials
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

burzynski research institute (BZYR) Key Developments

Burzynski Research Institute, Inc. Announces FDA Permission to Launch New Clinical Trial in Diffuse Intrinsic Brainstem Glioma

Burzynski Research Institute, Inc. announced that the U.S. Food and Drug Administration (FDA) has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). Study subjects will be placed in one of five treatment groups based on their age and whether or not they have received prior treatment for DIPG. The primary study endpoint is a decrease in the size of the tumor, either a partial response (>= 50% decrease in the size of the tumor) or a complete response (disappearance of the tumor). The study is in its final organizational stage and will begin accruing patients as soon as this organizational stage is completed.

Burzynski Research Institute, Inc. Announces Lifting of the FDA Partial Clinical Hold - Phase 3 Clinical Study Agreed Upon

The Burzynski Research Institute Inc. (BRI) announced that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted. The FDA has determined that under its IND the Company may initiate its planned Phase 3 study in newly diagnosed diffuse, intrinsic, brainstem glioma. The Company is continuing discussions with the Agency in an effort to finalize additional details of the phase 3 study protocol for the potential clinical trial. The FDA's decision to lift the clinical hold marks an important step in the development of Antineoplastons for the treatment of various forms of brain tumors in the US. At the same time, the Company is evaluating possible next steps for the Antineoplastons clinical program given the current progress and anticipated resource requirements of the ongoing program.

Burzynski Research Institute Elects Frederick Richard Schiff to Fill Vacancy on the Board of Directors

On July 3, 2013, the Board of Directors of Burzynski Research Institute unanimously elected Frederick Richard Schiff to fill a vacancy on the Board of Directors. Mr. Schiff is currently a lieutenant with the San Francisco Police Department who has worked at the Airport Bureau as the manager of Administrative Support Services since January, 2012.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BZYR:US $0.13 USD 0.00

BZYR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BZYR.
View Industry Companies

Industry Analysis


Industry Average

Valuation BZYR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BURZYNSKI RESEARCH INSTITUTE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at